Literature DB >> 25112470

Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease.

Anne E Holland1, Julio F Fiore, Emily C Bell, Nicole Goh, Glen Westall, Karen Symons, Leona Dowman, Ian Glaspole.   

Abstract

BACKGROUND AND OBJECTIVES: Little is known about the prevalence of anxiety in interstitial lung disease (ILD), and the contributors to depression are not clear. The aim of this study was to determine the prevalence and predictors of anxiety and depression in people with ILD.
METHODS: One hundred and twenty-four individuals with ILD (age 64 years (standard deviation 12), 48 idiopathic pulmonary fibrosis) participated. Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale to determine likely cases and borderline cases. Associations with demographic data, respiratory function, 6-min walk and Modified Medical Research Council Dyspnoea Scale (MMRC) were examined.
RESULTS: The prevalence of anxiety was 31%, with clinically significant anxiety in 12%. Depression was present in 23% of individuals, with 7% having clinically significant depression. Independent predictors of anxiety were a higher MMRC score (P = 0.005, odds ratio (OR) for case 2.60, 95% confidence interval 1.37 to 4.92) and higher nadir SpO2 during walking (P = 0.003, OR for case 1.16, 1.04-1.30). Independent predictors of depression were a higher MMRC score (P = 0.006, case OR 3.84, 1.25-11.78, borderline case OR 2.44, 1.14-5.19) and a greater number of comorbidities (P = 0.003, case OR 2.02, 0.97-4.21, borderline case OR 2.26, 1.30-3.93).
CONCLUSIONS: Anxiety and depression are present in a significant minority of individuals with ILD. Dyspnoea and comorbidities are important contributors that may be amenable to intervention.
© 2014 Asian Pacific Society of Respirology.

Entities:  

Keywords:  anxiety; comorbidity; depression; dyspnoea; interstitial lung disease

Mesh:

Year:  2014        PMID: 25112470     DOI: 10.1111/resp.12360

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  36 in total

Review 1.  Current best practice in rehabilitation in interstitial lung disease.

Authors:  Atsuhito Nakazawa; Narelle S Cox; Anne E Holland
Journal:  Ther Adv Respir Dis       Date:  2016-11-15       Impact factor: 4.031

2.  Outcome Measures for Clinical Trials in Interstitial Lung Diseases.

Authors:  Matthew R Lammi; Robert P Baughman; Surinder S Birring; Anne-Marie Russell; Jay H Ryu; Marybeth Scholand; Oliver Distler; Daphne LeSage; Catherine Sarver; Katerina Antoniou; Kristin B Highland; Otylia Kowal-Bielecka; Joseph A Lasky; Athol U Wells; Lesley Ann Saketkoo
Journal:  Curr Respir Med Rev       Date:  2015

3.  Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis.

Authors:  Ian N Glaspole; Alice L Watson; Heather Allan; Sally Chapman; Wendy A Cooper; Tamera J Corte; Samantha Ellis; Christopher Grainge; Nicole Goh; Peter Hopkins; Gregory Keir; Sacha Macansh; Annabelle Mahar; Yuben Moodley; Paul N Reynolds; Christopher J Ryerson; E Haydn Walters; Christopher J Zappala; Anne E Holland
Journal:  Eur Respir J       Date:  2017-08-17       Impact factor: 16.671

Review 4.  Optimizing quality of life in patients with idiopathic pulmonary fibrosis.

Authors:  Mirjam J G van Manen; J J Miranda Geelhoed; Nelleke C Tak; Marlies S Wijsenbeek
Journal:  Ther Adv Respir Dis       Date:  2017-01-01       Impact factor: 4.031

Review 5.  Comprehensive Care of the Lung Transplant Patient.

Authors:  Ayodeji Adegunsoye; Mary E Strek; Edward Garrity; Robert Guzy; Remzi Bag
Journal:  Chest       Date:  2016-10-08       Impact factor: 9.410

6.  The prevalence of obstructive sleep apnea in interstitial lung disease: a systematic review and meta-analysis.

Authors:  Yang Cheng; Yan Wang; Li Dai
Journal:  Sleep Breath       Date:  2021-01-06       Impact factor: 2.816

7.  Are idiopathic pulmonary fibrosis patients more anxious and depressive than patient's with other interstitial lung disease?

Authors:  Enver Yalnız; Gulru Polat; Fatma Demirci; Sami Deniz; Gulistan Karadeniz; Esra Aydınlı; Gorkem Vayisoglu; Aysu Ayrancı
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

8.  Patient-reported outcome measures in systemic sclerosis-related interstitial lung disease for clinical practice and clinical trials.

Authors:  Lesley Ann Saketkoo; Mary Beth Scholand; Matthew R Lammi; Anne-Marie Russell
Journal:  J Scleroderma Relat Disord       Date:  2020-03-05

9.  Patients with idiopathic pulmonary fibrosis with and without obstructive sleep apnea: differences in clinical characteristics, clinical outcomes, and the effect of PAP treatment.

Authors:  George Papadogiannis; Izolde Bouloukaki; Charalampos Mermigkis; Stylianos Michelakis; Christina Ermidou; Eleni Mauroudi; Violeta Moniaki; Nikolaos Tzanakis; Katerina M Antoniou; Sophia E Schiza
Journal:  J Clin Sleep Med       Date:  2021-03-01       Impact factor: 4.062

Review 10.  A systematic review of literature to evaluate the burden of physical and psychological symptoms and palliative care in patients diagnosed with idiopathic pulmonary fibrosis.

Authors:  M F van Jaarsveld; L Gwyther
Journal:  Afr J Thorac Crit Care Med       Date:  2019-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.